18F-FDG PET/CT在卵巢癌初诊与复发化疗监测中的预后价值
本文指出,关于FDG PET/CT阴性或阳性对卵巢癌无进展生存和总生存预后相关性的已发表经验多为异质性回顾性分析。已明确的要点包括:FDG肿瘤摄取与预后存在相关性;接受新辅助或辅助化疗的卵巢癌患者可分为治疗期间及治疗后肿瘤FDG摄取降低的应答者和FDG摄取保持稳定或升高的非应答者。
要点
- FDG肿瘤摄取与卵巢癌预后存在相关性。
- 化疗患者可分为FDG摄取降低的应答者和摄取稳定或升高的非应答者。
- 相关已发表经验多为异质性回顾性分析。
核心结论
- 已发表的经验多为异质性回顾性分析,FDG肿瘤摄取与卵巢癌预后存在相关性。
研究设计与样本
- 原文为对已发表经验的总结,提及的相关研究多为异质性回顾性分析。
主要发现
- FDG肿瘤摄取与预后存在相关性。
- 接受新辅助或辅助化疗的卵巢癌患者可分为治疗期间及治疗后肿瘤FDG摄取降低的应答者和肿瘤FDG摄取保持稳定或升高的非应答者。
局限性
- 原文指出相关已发表经验多为异质性回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Published experiences related to the prognostic relevance of negative or positive FDG PET/CT in patients treated for ovarian cancer for progression-free survival and overall survival are typically heterogeneous retrospective analyses. Several points have been well defined, these are as follows: (a) there is a correlation between FDG tumor uptake and prognosis; (b) ovarian cancer patients treated by neoadjuvant or adjuvant chemotherapy can be divided into responders with reduction in tumor FDG uptake during and after treatment and nonresponders where tumor FDG uptake remains stable or increases after treatment;
引用
- Rubello D, Marzola MC, Colletti PM, et al. The Prognostic Value of 18F-FDG PET/CT in Monitoring Chemotherapy in Ovarian Cancer Both at Initial Diagnosis and at Recurrent Disease. Clin Nucl Med. 2018. PMID: 30106857. doi:10.1097/RLU.0000000000002227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。